Lysine-specific demethylase inhibitor (1C) is primarily utilized in the field of cancer research and therapy. It functions by targeting and inhibiting lysine-specific demethylases, enzymes that play a crucial role in the regulation of gene expression by removing methyl groups from histone proteins. This inhibition leads to the reactivation of tumor suppressor genes and the suppression of oncogenes, making it a promising candidate for epigenetic cancer treatment. Researchers are exploring its potential in treating various cancers, including leukemia, breast cancer, and lung cancer, where abnormal demethylase activity contributes to disease progression. Additionally, it is being studied for its role in enhancing the efficacy of other anticancer therapies, such as chemotherapy and immunotherapy, by modulating the epigenetic landscape of cancer cells.